非典型黑素细胞病变诊断与管理中二次病理意见的影响:意大利黑色素瘤协作组(IMI)与EORTC黑色素瘤组的前瞻性研究
该前瞻性研究通过意大利黑色素瘤协作组(IMI)全国「二次意见平台」对230例患者的254个非典型黑素细胞增生及疑难皮肤肿瘤进行专科皮肤病理医生复审,评估影响患者管理的主要诊断不一致率。转诊诊断与专家复审不一致90/254例(35.4%),其中60/90例(66.7%)为改变临床管理的主要不一致;51/60例主要不一致经EORTC黑色素瘤病理医生盲法复评,最终观察者间一致率90%。
要点
- 转诊诊断与专家复审不一致90/254例(35.4%),其中60/90例(66.7%)为改变临床管理的主要不一致。
- 90例不一致病例中新诊断最常见于WHO通路I(64/90),其次为WHO通路IV(12/90)。
- 51/60例主要不一致经EORTC病理医生盲法复评,最终观察者间一致率90%。
核心结论
- 对非典型黑素细胞病变进行二次意见影响临床管理,虽比例较小但仍显著。
- 中央专家复审支持病理医生和临床医生限制过度治疗和治疗不足的风险。
研究设计与样本
- 前瞻性临床研究,通过意大利黑色素瘤协作组(IMI)全国「二次意见平台」由专科皮肤病理医生复审新诊断或疑似非典型黑素细胞增生及疑难皮肤肿瘤。
- 样本包括230例患者的254个病变。
- 转诊与专科复审之间的主要诊断不一致由欧洲癌症研究与治疗组织(EORTC)黑色素瘤病理医生小组盲法复评。
主要发现
- 转诊诊断与专家复审不一致90/254例(35.4%)。
- 90例不一致中60/90例(66.7%)为改变患者临床管理的主要不一致。
- 90例不一致病例中新诊断最常见于WHO通路I(64/90),其次为WHO通路IV(12/90)。
- 51/60例主要不一致经EORTC黑色素瘤病理医生盲法复评,最终观察者间一致率90%。
关键数值与推荐
- 转诊诊断最常见为非典型黑素细胞痣不同亚型(74/254,29.2%)、浸润性黑色素瘤(61/254,24.0%)、非典型黑素细胞增生(37/254,14.6%)、AST(21/254,8.3%)和原位黑色素瘤(17/254,6.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical value of an expert pathological review in patients with an atypical melanocytic lesion diagnosis remains unclear. Herein, we evaluate its impact in a prospective clinical study. METHODS: Patients with newly diagnosed or suspected atypical melanocytic proliferations and challenging skin tumours were reviewed prospectively by a specialised dermatopathologist through the nationwide 'Second Opinion Platform' of the Italian Melanoma Intergroup (IMI) network. The primary aim was the rate of major discrepancies that impacted patient management. Major discrepancies in diagnosis between referral and specialised review were blindly re-analysed by a panel of European Organisation for Research and Treatment (EORTC) Melanoma pathologists. RESULTS: The samples submitted to central review included 254 lesions from 230 patients. The most frequent referral diagnoses were atypical melanocytic nevi of different subtypes (74/254, 29.2%), invasive melanomas (61/254, 24.0%), atypical melanocytic proliferations (37/254, 14.6%), AST (21/254, 8.3%) and in situ melanomas (17/254, 6.7%). There was disagreement between referral diagnosis and expert review in 90/254 cases (35.4%). Most importantly, 60/90 (66.7%) were major discordances with a change to the patient's clinical management. Among the 90 discordant cases, the most frequent new diagnosis occurred in World Health Organisation (WHO) Pathway I, followed by WHO Pathway IV (64/90 and 12/90, respectively). In total, 51/60 cases with major discrepancies were blindly re-evaluated by EORTC Melanoma pathologists with a final interobserver agreement in 90% of cases. CONCLUSION: The study highlights that a second opinion for atypical melanocytic lesions affects clinical management in a minor, but still significant, proportion of cases. A central expert review supports pathologists and clinicians to limit the risk of both over- and under-treatment.
引用
- Massi D, Szumera-Ciećkiewicz A, Alos L, et al. Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group. Eur J Cancer. 2023. PMID: 37280145. doi:10.1016/j.ejca.2023.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。